Analyst Sarita Kapila of Morgan Stanley maintained a Hold rating on Roche Holding AG, retaining the price target of CHF286.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sarita Kapila has given her Hold rating due to a combination of factors influencing Roche Holding AG’s financial performance. The company’s Q2 and H1 2025 results showed a slight outperformance against market expectations, with a 1% sales beat primarily driven by the Pharmaceuticals division, which exceeded expectations by 2%. However, this was somewhat counterbalanced by a 4% miss in the Diagnostics division, highlighting some underlying challenges.
Despite the overall positive financial results, including a 5% beat in core EPS due to a lower tax rate, the outlook remains cautious. Roche reiterated its FY’25 guidance, projecting moderate sales growth and high single-digit EPS growth, but with anticipated currency impacts potentially affecting these figures. The upcoming launch of biosimilars in the US by the end of 2026 and the delay in Phase 3 data for fenebrutinib also contribute to a conservative stance, justifying the Hold rating as the company navigates these mixed signals and external pressures.
Kapila covers the Healthcare sector, focusing on stocks such as Roche Holding AG, GlaxoSmithKline, and Sanofi. According to TipRanks, Kapila has an average return of -1.0% and a 53.85% success rate on recommended stocks.
In another report released today, Jefferies also maintained a Hold rating on the stock with a CHF270.00 price target.